MarketFriction

Syngene International Ltd

NSE SYNGENE · BSE 539268 · Healthcare Research, Analytics & Technology
₹361.30 -1.09%
NSE close2026-10-01
52 week range360.40 - 678.95
Market cap₹14,823 Cr.
P/E50.0
IPO 2015 · +189% since Nifty 500Nifty Smallcap 50Nifty Smallcap 100Smallcap 250 Price band 20% Delivery 53.9%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales910.10853.50916.90789.70891.00943.701,018.00874.50910.60917.101,036.50736.00
Expenses656.00622.00600.00619.90646.20660.10674.40668.10711.10707.90733.10645.20
Operating Profit254.10231.50316.90169.80244.80283.60343.60206.40199.50209.20303.4090.80
OPM %27.92%27.12%34.56%21.50%27.47%30.05%33.75%23.60%21.91%22.81%29.27%12.34%
Other Income14.2025.6016.1050.1016.5018.3018.9017.7015.40-55.2016.2011.80
Interest13.0010.8012.9011.7013.1012.4015.9011.6013.2011.9012.109.60
Depreciation104.60108.10111.10106.90110.90108.70106.10111.20116.50113.70111.50112.20
Profit before tax150.70138.20209.00101.30137.30180.80240.50101.3085.2028.40196.00-19.20
Tax %22.69%19.32%9.76%25.27%22.72%27.49%23.78%14.41%21.24%47.18%24.54%-53.12%
Net Profit116.50111.50188.6075.70106.10131.10183.3086.7067.1015.00147.90-9.00
EPS in Rs2.902.774.691.882.643.264.552.151.670.373.67-0.22
Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,4231,8262,0122,1842,6043,1933,4893,6423,7393,600
Expenses9491,2891,3941,5071,8612,2512,4722,5982,8172,797
Operating Profit4745376186787439421,0171,045921803
OPM %33%29%31%31%29%30%29%29%25%22%
Other Income537515394756377101-9-12
Interest23323528244547534947
Depreciation131164219274310366426433453454
Profit before tax372415517469484594621660411290
Tax %18%20%20%14%18%22%18%25%23%
Net Profit305332412405396464510496317221
EPS in Rs7.648.2910.3010.129.8811.5712.6912.337.865.49
Dividend Payout %7%3%0%0%10%11%10%10%16%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%11%5%-3%
Compounded Profit Growth%0%-8%-42%
Stock Price CAGR4%-10%-23%-41%
Return on Equity%11%10%8%
Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital200200400400401401402402403
Reserves1,5201,7681,7762,4212,8973,2173,8564,3244,436
Borrowings7878137738931,022815555578458
Other Liabilities6819221,2141,1691,2451,3981,3391,4911,757
Total Liabilities3,1893,7044,1634,8835,5645,8316,1526,7967,055
Fixed Assets1,0301,3772,0202,2012,3932,6672,8502,8023,000
CWIP1552742342373461778381,2661,046
Investments1587167767021,034918548647741
Other Assets1,8461,3371,1331,7431,7902,0691,9162,0812,268
Total Assets3,1893,7044,1634,8835,5645,8316,1526,7967,055
Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity4466306777015818241,0421,168915
Cash from Investing Activity-349-646-424-629-611-653-494-744-839
Cash from Financing Activity-79-72-22658-31-342-551-142-215
Net Cash Flow18-8828130-62-172-4281-138
Free Cash Flow824734255105305553398547
CFO/OP111%135%127%116%92%102%115%123%107%
Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days686872797161465350
Inventory Days8230184187141946056
Days Payable195154156167113109100136138
Cash Conversion Cycle-44-56-66-47459240-23-32
Working Capital Days-48-103-172-66-43-14-27-51-68
ROCE %17%17%14%13%15%15%13%10%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters54.79%54.79%54.79%54.72%54.72%52.74%52.74%52.68%52.68%52.68%52.68%52.59%
FIIs23.55%21.20%20.92%20.64%20.72%20.65%19.47%16.51%16.31%14.96%13.91%11.82%
DIIs11.70%14.63%15.80%16.78%17.49%19.52%21.50%24.05%24.62%25.83%26.44%28.01%
Public9.47%9.07%8.18%7.44%6.74%6.79%5.99%6.45%6.08%6.22%6.69%7.15%
Others0.48%0.32%0.31%0.43%0.34%0.29%0.29%0.31%0.30%0.29%0.29%0.43%
No. of Shareholders1,25,9921,21,8801,15,8501,20,0181,07,3381,28,8061,25,0901,42,3101,36,0611,31,7501,35,6051,42,277

Fundamentals

Market Cap₹ 14,823 Cr.
Current Price₹ 367
Stock P/E50.0
Book Value₹ 120
ROCE9.99 %
ROE7.78 %
Dividend Yield0.34 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-3%
Compounded Profit Growth (TTM)-42%
Consolidated figures.
Valuation
Market capRs 14,544 Cr
Enterprise valueRs 14,335 Cr
P/E (TTM)65.81x
Price to book3.08x
Price to sales4.04x
EV / EBITDA18.12x
EV / EBIT42.51x
EV / sales3.98x
Price to cash flow12.46x
Earnings yield1.52%
Dividend yield0.35%
P/E, 3-year average55.23x
P/B, 3-year average6.47x
P/E, 5-year average55.98x
P/B, 5-year average6.88x
Profitability
Operating margin (excl. other income)28.68%
Operating margin (incl. other income)31.45%
EBITDA margin21.97%
Pre-tax margin8.07%
Net profit margin6.14%
Net margin, latest quarter-1.22%
ROE11.05%
ROCE14.09%
ROA7.66%
ROE, 3-year average12.48%
ROCE, 3-year average14.38%
ROA, 3-year average8.11%
ROE, 5-year average13.31%
ROCE, 5-year average14.14%
ROA, 5-year average8.17%
ROIC (approx.)5.61%
Tax rate24.81%
Other income / net worth2.13%
Growth
Sales growth (latest year)4.41%
Profit growth (latest year)-2.71%
Sales CAGR, 3 years11.83%
Sales CAGR, 5 years12.60%
Profit CAGR, 3 years7.83%
Profit CAGR, 5 years3.78%
Sales growth QoQ-28.99%
Profit growth QoQ-106.09%
Sales growth YoY (latest quarter)-15.84%
Profit growth YoY (latest quarter)-110.38%
Per share
EPS (TTM)Rs 5.49
EPS (latest year)Rs 12.33
EPS (latest quarter)Rs -0.22
EPS, 3-year averageRs 12.19
EPS, 5-year averageRs 11.32
Book value per shareRs 117.43
Sales per shareRs 89.44
Cash flow per shareRs 29.01
Free cash flow per shareRs 13.59
Dividend per share (latest year)Rs 1.25
Dividend per share, 3-year averageRs 1.25
Dividend per share, 5-year averageRs 1.19
Dividends
Dividend payout10.14%
Dividend payout, 3-year average10.27%
Dividend payout, 5-year average10.23%
Efficiency
Asset turnover0.54x
Fixed asset turnover1.30x
Inventory turnover8.37x
Inventory days44 days
Debtor days53 days
Debtors turnover6.92x
Creditor days138 days
Cash conversion cycle-32 days
Working capital days-68 days
Leverage
Total debtRs 578 Cr
Cash and bankRs 787 Cr
Net debtRs -209 Cr
Debt to equity0.12x
Net debt / EBITDA-0.26x
Interest coverage7.21x
Current ratio (filing 2026-03-31)1.38x
Quick ratio (filing 2026-03-31)1.29x
Trade payables (filing 2026-03-31)Rs 348 Cr
Owners' fund to total sources69.55%
Debt to assets8.50%
Cash flow
Cash from Operating Activity (latest year)Rs 1,168 Cr
Cash from Investing Activity (latest year)Rs -744 Cr
Cash from Financing Activity (latest year)Rs -142 Cr
Net Cash Flow (latest year)Rs 281 Cr
Free cash flow (latest year)Rs 547 Cr
FCFE (approx.: FCF + change in debt)Rs 570 Cr
Cash from ops / profit, 5 years2.08x
Sales to cash flow3.12x
Statement figures
Net sales (TTM)Rs 3,600 Cr
Net sales (latest year)Rs 3,642 Cr
Sales (latest quarter)Rs 736 Cr
Operating profit excl. other income (latest year)Rs 1,045 Cr
Operating profit (latest quarter)Rs 91 Cr
Other income (TTM)Rs -12 Cr
EBITDA (TTM)Rs 791 Cr
PBDT (TTM)Rs 744 Cr
Profit before tax (TTM)Rs 290 Cr
Tax (latest year)Rs 164 Cr
Net profit (TTM)Rs 221 Cr
Net profit (latest year)Rs 496 Cr
Net profit (latest quarter)Rs -9 Cr
Depreciation (TTM)Rs 454 Cr
Depreciation (latest quarter)Rs 112 Cr
Interest (TTM)Rs 47 Cr
Cost of goods sold (latest year)Rs 1,301 Cr
Total expenditure (latest year)Rs 2,598 Cr
Total income (latest year)Rs 3,743 Cr
Share capitalRs 402 Cr
ReservesRs 4,324 Cr
Shareholders' fundsRs 4,727 Cr
Total assetsRs 6,796 Cr
Net blockRs 2,802 Cr
Capital work in progressRs 1,266 Cr
InvestmentsRs 647 Cr
ReceivablesRs 527 Cr
InventoryRs 156 Cr
Other liabilitiesRs 1,491 Cr
Shares outstanding (crore)40.25
Ownership
Promoter holding52.59% (-0.09 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 65.8 is at the 65th percentile of its own 7.4-year range (median 58.4, low 31.6, high 81.8).
P/B 3.08 is the lowest in 7.4 years (median 8.41).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodSYNGENENifty 50Difference
1 week-5.0%-2.8% -2.2 pts
1 month-10.1%-6.8% -3.3 pts
3 months-17.9%-7.6% -10.3 pts
6 months-7.3%+0.4% -7.7 pts
1 year-43.3%-9.9% -33.4 pts
2 years-59.6%-13.6% -46.0 pts
3 years-55.1%+14.2% -69.2 pts
5 years-41.3%+27.9% -69.2 pts
113 mutual fund schemes hold about ₹4,773 Cr. Over three months 87 bought more and 11 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Nippon India Small Cap Fund0.65%534 +13%
ICICI Pru Multi Cap Fund1.63%319 +62%
ICICI Pru Multi Cap Fund1.63%306 +62%
SBI Multi Asset Allocation Fund(A1.34%281 +3%
Nippon India Multi Cap Fund0.47%264 +8%
Nippon India Focused Fund2.78%240 +14%
ICICI Pru Healthcare Fund-3.29%230 +39%
DSP ELSS Tax Saver Fund0.94%156 +10%
ICICI Pru ELSS-Tax Saver Fund1.06%151 +9%
DSP Large & Mid Cap Fund0.77%142 +8%
Nippon India Pharma Fund1.48%140 +6%
Mirae Asset Focused Fund1.91%129 +1%
Mirae Asset Focused Fund1.91%127 +1%
DSP Aggressive Hybrid Fund1.05%124 +12%
SBI Contra Fund0.24%114 +100%
ICICI Pru Multi Asset Allocation Fund0.13%112 +8%
ICICI Pru Large & Mid Cap Fund0.27%91 +2%
DSP Flexi Cap Fund0.70%87 +9%
SBI Healthcare Opp Fund1.24%72 +100%
DSP Midcap Fund0.30%64 +7%
Tata Flexi Cap Fund1.48%54 +19%
Nippon India Innovation Fund1.70%53 +4%
Invesco India Smallcap Fund0.33%52 +100%
Bandhan Flexi Cap Fund0.67%50 +52%
DSP Healthcare Fund1.31%50 +15%

Red flags

F-score 5 of 8
lookAuditor change Auditor change 2026-04-29: Syngene International Limited has informed the Exchange regarding Change in Auditors of the company.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹736 Cr -15.8% vs Jun 2025. Net loss ₹9 Cr.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Indegene Ltd14,58035.018.8 %
Suven Life Sciences Ltd9,176-79.5 %
Vimta Labs Ltd2,64232.725.2 %
Fabtech Technologies Ltd66113.613.6 %
Bilcare Ltd22911.57.06 %
Take Ltd20835.218.5 %
Novelix Pharmaceuticals Ltd19955.110.9 %
Jeevan Scientific Technology Ltd16346.75.01 %
Adeshwar Meditex Ltd2419.45.21 %
Vanta Bioscience Ltd151331.19 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-06-25Dividend - Rs 1.25 Per Share
2025-06-27Dividend - Rs 1.25 Per Share
2024-06-28Dividend - Rs 1.25 Per Share
2023-06-30Dividend - Rs 0.50 Per Share/Special Dividend - Rs 0.75 Per Share
2022-06-30Dividend - Rs 0.50 Per Share/Special Dividend - Rs 0.50 Per Share
2021-07-13 Annual General Meeting
2019-07-16 Dividend - Rs 0.50 Per Share
2019-06-11 Bonus 1:10.5000
2018-07-17 Dividend Re - Re 1 Per Share
2017-07-20 Dividend - Rs 1/- Per Share
2016-03-17 Interim Dividend - Re 1/- Per Share (Purpose Revised)
DateTypeWhat it says
2026-09-24General UpdatesIntimation of cancellation of meeting with Analyst/Institutional Investors
2026-09-21ResignationResignation of Director/KMP/SMP
2026-09-21ResignationResignation of Mr. Pramuch Goel as Head Corporate Affairs & Communications and a member of Executive Committee (Senior Management Personnel) of the co...
2026-09-21Concall / analyst meetSchedule of meet
2026-09-12Concall / analyst meetSchedule of meet
2026-09-11Concall / analyst meetSchedule of meet
2026-09-10General UpdatesThe Communication regarding remittance of final dividend for the FY 2025-26.
2026-09-01UpdatesGrant of Performance Share Units under Syngene Long Term Incentive Performance Share Plan (PSP) 2023 (Plan).
2026-08-25Concall / analyst meetSchedule of meet
2026-08-24AcquisitionAcquisition
2026-08-24Concall / analyst meetSchedule of meet
2026-08-10Concall / analyst meetSchedule of meet
2026-08-06Concall / analyst meetTranscript
2026-07-31Shareholder meetingVoting results.
2026-07-30Concall / analyst meetLink of Recording
2026-07-29Investor PresentationInvestor Presentation
2026-07-29Shareholder meetingProceedings of Annual General Meeting held on July 29, 2026
2026-07-29ResignationResignation of Director/KMP/SMP
2026-07-29ResignationResignation of Mr Kush Parmar as Independent Director of the company w.e.f. July 29, 2026.
2026-07-29Press ReleaseA press release dated July 29, 2026, titled "Q1 FY27 revenue from operations at Rs. 736 Cr; Operating EBITDA at Rs. 91 Cr".
2026-07-29Board meeting outcomeSyngene International Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-22Concall / analyst meetSchedule of meet
2026-07-14Change in ManagementChange in Management
2026-07-08Resignation of Statutory AudResignation of Statutory Auditor
2026-07-08ResignationResignation of M/s B S R & Co. LLP, Statutory Auditor of material subsidiary of the company w.e.f. July 07, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)

Quick answers

What is the market cap of Syngene International Ltd?

Syngene International Ltd (SYNGENE) has a market capitalisation of Rs 14,823 Cr. at the 2026-10-01 close.

What is the P/E ratio of Syngene International Ltd?

Syngene International Ltd trades at a P/E of 50.0 on trailing twelve-month profit, at the 2026-10-01 close.

What were Syngene International Ltd's latest quarterly results?

In the Jun 2026 quarter, Syngene International Ltd sales was Rs 736 Cr (-15.8% vs Jun 2025) with a net loss of Rs 9 Cr.

What is the 52-week high and low of Syngene International Ltd?

The 52-week high is Rs 678.95 and the 52-week low is Rs 360.40.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03